Navigation Links
Collagen Matrix, Inc. Receives FDA 510(k) Clearance for New Collagen Dental Membrane Based on Porcine Collagen Platform Technology
Date:10/1/2010

FRANKLIN LAKES, N.J., Oct. 1 /PRNewswire/ -- Collagen Matrix, Inc., the leader in collagen- and mineral-based matrix engineering, announced today that it has received FDA's 510(k) clearance of a new Collagen Dental Membrane derived from porcine dermis indicated for use in oral surgical procedures involving guided tissue and bone regeneration.  

This new Collagen Dental Membrane is a nonfriable, conformable, resorbable, membrane matrix consisting of highly purified type I and III collagen derived from porcine dermis.  The proprietary purification process results in a purified intact collagen tissue membrane with negligible non-collagenous materials. As the area of regenerative medicine in the dental market continues to expand, the demand for collagen membranes has increased worldwide.  Each of Collagen Matrix's six distinct Collagen Dental Membranes has features that distinguish one from the other.  These distinguishing features have been driven by the needs and input from the clinicians.  Design requirements such as handling, in vivo stability, shape, conformability or rigidity, have been optimized and adjusted for each dental membrane based on clinical feedback and specific treatment needs.

The significance of the new technology is the use of porcine tissue rich in collagen, whereby the proprietary treatment eliminates most, if not all, of the non-collagenous materials resulting in a highly purified intact collagen matrix.  This treatment maintains the intact collagen framework while eliminating associated non-collagenous materials.  The purity of the Company's intact collagen tissue matrix surpasses most tissue-based products currently on the market.      

"The introduction of porcine tissue to our technology coincides nicely with the facility expansion of Collagen Matrix occurring this year.  A space will be dedicated to the processing of porcine tissue.  The possible clinical uses of this new material are broad and add yet another dimension to the breadth of collagen expertise in the Company's intellectual property.  This is another platform on which we plan to build and innovate for future products in key areas of growth," said Shu-Tung Li, Ph.D., Founder and CEO of Collagen Matrix.

Collagen Matrix, Inc. is a leader in the design and engineering of collagen- and mineral-based extracellular matrices for tissue and organ repair and regeneration.  Since its inception in 1997, the Company has received many government grants for the development of collagen-based matrix products in the areas of neurological, vascular, urological, and orthopedic tissue regeneration applications.  The Company currently manufactures collagen-based finished medical devices in the areas of neurosurgery, oral surgery, orthopedic-spine surgery, and wound care.  More information about the Company can be found at www.collagenmatrix.com.

Contact: Peggy Hansen, RAC

 Vice President, Clinical, Regulatory, Quality Assurance, and Marketing


'/>"/>
SOURCE Collagen Matrix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biosynthetic corneas formulated with recombinant collagen restore vision and nerve growth
2. Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage Tissue
3. Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler
4. Xiaoguang Meng receives honorary master of engineering from Stevens
5. AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy
6. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
7. NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
8. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
9. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
10. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
11. Keck Graduate Institute Receives $3.6 Million NIH Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017   Instrument Business Outlook ( ... MN ) the 2016 Company of the ... newsletter tracking developments in the analytical and life ... consistently achieved outstanding technical, operational and financial results ... of IBO. "In 2016, Bio-Techne capitalized on opportunities ...
(Date:1/23/2017)...  Spherix Incorporated (Nasdaq: SPEX ) an ... technology and monetization of intellectual property, today provided an ... Anthony Hayes , Chief Executive Officer of Spherix, ... communicate with shareholders about the status of existing monetization ... other patent assets that fit with our current holdings.  ...
(Date:1/23/2017)... PA (PRWEB) , ... January 23, 2017 , ... ... Thomas has been appointed Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. ... of Madras in India. , Dr. Thomas’ career as an academic and ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific ... healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices in ... scientific consultants and contractors. This is the latest step in G&L’s expansion of ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/16/2016)... NEW YORK , Dec. 16, 2016 The global ... reach USD 12.14 billion by 2021 from USD 5.31 billion in ... ... market is mainly driven by technological advancements in medical devices, launch ... devices, rising preference for wireless connectivity among healthcare providers, and increasing ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):